Large collaborative registries and real-world data to manage amyloid-related imaging abnormalities
To the Editor Hall et al describe a patient with prodromal Alzheimer disease who developed 6 relapsing episodes of amyloid-related imaging abnormality edema (ARIA-E) over 44 months of treatment within the aducanumab long-term extension period. Together with the recently reported 41.3% risk of ARIA i...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
April 25, 2022
|
| In: |
JAMA neurology
Year: 2022, Volume: 79, Issue: 6, Pages: 633-634 |
| ISSN: | 2168-6157 |
| DOI: | 10.1001/jamaneurol.2022.0731 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1001/jamaneurol.2022.0731 Verlag, lizenzpflichtig, Volltext: https://jamanetwork.com/journals/jamaneurology/fullarticle/2791266 
|
| Author Notes: | Fabrizio Piazza, Lutz Frölich, Alessandro Padovani |
| Summary: | To the Editor Hall et al describe a patient with prodromal Alzheimer disease who developed 6 relapsing episodes of amyloid-related imaging abnormality edema (ARIA-E) over 44 months of treatment within the aducanumab long-term extension period. Together with the recently reported 41.3% risk of ARIA in the Phase 3 Study of Aducanumab in Early Alzheimer’s Disease (EMERGE and ENGAGE) trials, we believe this work is of particular interest as it points out ARIA as a timely research and clinical priority, prompting the urgent need to define standardized guidelines for the treatment and follow-up monitoring of such side events. |
|---|---|
| Item Description: | Gesehen am 05.02.2024 |
| Physical Description: | Online Resource |
| ISSN: | 2168-6157 |
| DOI: | 10.1001/jamaneurol.2022.0731 |